Marshall Wace
NVCR icon

Marshall Wace’s NovoCure NVCR Stock Holding History

Marshall Wace’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,034,978
Closed -$13.4M – 3321
2025
Q3 		$13.4M Sell
1,034,978
-379,621
-27% -$5.07M 0.01% 814
2025
Q2 		$25.2M Sell
1,414,599
-392,992
-22% -$6.85M 0.03% 501
2025
Q1 		$32.2M Buy
1,807,591
+1,536,639
+567% +$34.9M 0.04% 385
2024
Q4 		$8.07M Sell
270,952
-508,718
-65% -$10.8M 0.01% 875
2024
Q3 		$12.2M Buy
779,670
+282,196
+57% +$5.12M 0.01% 684
2024
Q2 		$8.52M Sell
497,474
-272,053
-35% -$4.78M 0.01% 806
2024
Q1 		$12M Buy
769,527
+422,099
+121% +$6.21M 0.02% 684
2023
Q4 		$5.19M Buy
347,428
+284,067
+448% +$3.8M 0.01% 899
2023
Q3 		$1.02M Sell
63,361
-153,241
-71% -$4.42M ﹤0.01% 1496
2023
Q2 		$8.99M Buy
216,602
+200,516
+1,247% +$12.5M 0.02% 784
2023
Q1 		$967K Buy
+16,086
New +$1.29M ﹤0.01% 1832
2022
Q3 		– Sell
-104,760
Closed -$7.28M – 3660
2022
Q2 		$7.28M Buy
+104,760
New +$7.89M 0.02% 1092
2022
Q1 		– Sell
-3,572
Closed -$268K – 3804
2021
Q4 		$268K Buy
+3,572
New +$359K ﹤0.01% 3067
2021
Q1 		– Sell
-2,951
Closed -$511K – 2746
2020
Q4 		$511K Buy
+2,951
New +$404K ﹤0.01% 1449
2018
Q2 		– Sell
-16,500
Closed -$360K – 803
2018
Q1 		$360K Buy
+16,500
New +$355K 0.01% 430

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Marshall Wace's NVCR Position: Q4 2025 in Review

Marshall Wace sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 1,034,978 shares — an estimated $13.4M sold.

Marshall Wace first reported a position in NVCR in Q1 2018 and held it in 15 quarters. The position peaked at $32.2M in Q1 2025. 239 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • Marshall Wace reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • Marshall Wace sold 1,034,978 NovoCure shares in Q4 2025, an estimated $13.4M.
  • Marshall Wace first reported a position in NovoCure in Q1 2018 and held it in 15 quarters.
  • Marshall Wace's NovoCure position peaked at $32.2M in Q1 2025.
  • 239 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.